Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients

被引：0

作者：

Joseph, Nisha ^{[1
]}

Kaufman, Jonathan ^{[1
]}

Lonial, Sagar ^{[1
]}

Hofmeister, Craig ^{[1
]}

Dhodapkar, Madhav ^{[1
]}

Gupta, Vikas ^{[1
]}

DiCamillo, Sara ^{[1
]}

Roberts, Danielle ^{[1
]}

Boise, Lawrence ^{[1
]}

Nooka, Ajay ^{[1
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-141

引用

页码：S113 / S113

页数：1

共 50 条

[31] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTD) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-Risk Patients in Cassiopeia
Sonneveld, Pieter
Attal, Michel
Perrot, Aurore
Hulin, Cyrille
Caillot, Denis
Facon, Thierry
Leleu, Xavier
Belhadj, Karim
Karlin, Lionel
Benboubker, Lotfi
Levin, Mark-David
Minnema, Monique C.
Westerman, Matthijs
Delforge, Michel
Zweegman, Sonja
Pei, Lixia
de Boer, Carla
Vanquickelberghe, Veronique
Kampfenkel, Tobias
Moreau, Philippe
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 124 - 126
[32] Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Manasanch, Elisabet E.
Weber, Donna
Thomas, Sheeba K.
Turturro, Francesco
Shah, Nina
Popat, Uday R.
Nieto, Yago
Bashir, Qaiser
Munoz, Silvia C.
Landry, Ashley
Mendoza, Kathleen
Champlin, Richard E.
Qazilbash, Muzaffar H.
Orlowski, Robert Z.
BLOOD, 2015, 126 (23)
[33] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Moreau, Philippe
Dimopoulos, Meletios A.
Quach, Hang
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels W. C. J.
Katodritou, Eirini
Schjesvold, Fredrik
Sureda Balari, Anna
Rosinol, Laura
Delforge, Michel
Roeloffzen, Wilfried
Driessen, Christoph
Vangsted, Annette
Einsele, Hermann
Spencer, Andrew
Hajek, Roman
Jurczyszyn, Artur
Lonergan, Sarah
Liu, Yanfang
Wang, Jianping
Vieyra, Diego
van Brummelen, Emilie M. J.
Vanquickelberghe, Veronique
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Boccadoro, Mario
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S550 - S551
[34] Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
Silbermann, Rebecca
Laubach, Jacob
Kaufman, Jonathan L.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Gries, Katharine S.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 1146 - 1149
[35] Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
Dimopoulos, Meletios
Sonneveld, Pieter
Rodriguez-Otero, Paula
Hang Quach
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels
Katodritou, Eirini
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Moreau, Philippe
Boccadoro, Mario
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S30 - S31
[36] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
Rodriguez-Otero, Paula
Moreau, Philippe
Dimopoulos, Meletios Athanasios
Beksac, Meral
Perrot, Aurore
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels W. C. J.
Schjesvold, Fredrik
Delforge, Michel
Einsele, Hermann
Spencer, Andrew
Lonergan, Sarah
Vieyra, Diego
Sitthi-Amorn, Anna
Carson, Robin L.
Blade, Joan
Boccadoro, Mario
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
Sonneveld, Pieter
Attal, Michel
Perrot, Aurore
Hulin, Cyrille
Caillot, Denis
Facon, Thierry
Leleu, Xavier
Belhadj-Merzoug, Karim
Karlin, Lionel
Benboubker, Lofti
Levin, Mark-David
Minnema, Monique
Westerman, Matthijs
Delforge, Michel
Zweegman, Sonja
Pei, Lixia
de Boer, Carla
Vanquickelberghe, Veronique
Kampfenkel, Tobias
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E3
[38] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Maclachlan, Kylee H.
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Shekarkhand, Tala
Rueda, Colin
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Lesokhin, Alexander
Usmani, Saad Z.
BLOOD, 2023, 142
[39] Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
Wang, Yin-Che
Lin, Cheng-Hsien
Su, Yu-Chen
Teng, Chieh-Lin Jerry
HEMATOLOGY, 2025, 30 (01)
[40] Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma
Rosinol, Laura
Hebraud, Benjamin
Oriol, Albert
Colin, Anne-Laurene
Tamayo, Rafael Rios
Hulin, Cyrille
Blanchard, Maria Jesus
Caillot, Denis
Balari, Anna Sureda
Hernandez, Miguel T.
Arnulf, Bertrand
Mateos, Maria-Victoria
Macro, Margaret
San-Miguel, Jesus
Belhadj, Karim
Lahuerta, Juan-Jose
Garelik, M. Brigid
Blade, Joan
Moreau, Philippe
Attal, Michel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E1 - E2

← 1 2 3 4 5 →